Corporate Social Responsibility

BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer, infectious and other serious diseases. The aim of the Company and its core business model is to provide novel therapies and vaccines to people worldwide and thus, help to improve their lives.

Our core values form the basis of everything we do. We are:


Innovation and innovative thinking in all areas of our work are, therefore, the cornerstone of our success.


Passion and enthusiasm guide our day-to-day work and everything we do.


Common unity forms the foundation we build on in order to reach our ambitious goals successfully as a team—both between colleagues and interacting with our partners.

Throughout our work we are committed to being transparent, acting with integrity, protecting the environment and respecting human rights. These values form the unchanging basis of our work and, above all, our very own expectations of ourselves.

We have signed the United Nations Global Compact and support the Sustainable Development Goals (SDGs). In particular, our work contributes to the third SDG 3 – the promotion of good health and well-being for all people at all ages.

In March 2022, we published our latest Sustainability Report. It shows us where we stand and in which areas we need to improve. For our stakeholders this report offers a deep dive into our wider responsibility.

Sustainability Report 2022

We are responsible not only for our business, but also for the way we conduct this business. Explore our Sustainability Report 2022 and you are welcome to send us your suggestions and comments.

Group-wide management of Corporate Social Responsibility

As a biotech company with research and commercial manufacturing, we bear responsibility not only for our business, but also for the way our business is conducted. Ultimate responsibility for all CSR topics rests with the entire Management Board, which is supported strategically by the CSR Steering Board and operationally by the CSR Team. Our Sustainability Reports underline how we are anchoring responsibility in our core business.

Company Ratings

BioNTech has been rated as a company with a high corporate social responsibility as well as environmental social governance (ESG).

The ISS ESG's Corporate Rating provides investors with highly relevant, material and forward-looking ESG data and performance assessments. Originally developed by oekom research, the methodology has been consistently updated for more than 25 years, to deliver high-quality and in-depth research on companies' sustainability performances.

The Corporate Social Responsibility (CSR) Awards aim to acknowledge CSR successes, raise sustainability awareness, and share the CSR experiences with organizations looking to promote and exercise corporate responsibility.

Our Materiality Matrix

BioNTech identified the most important and the material CSR topics through a multi-step and cross-functional process. This was based on the analyses of relevant sustainability standards (e. g., GRI, SASB, NASDAQ ESG Reporting Guide) and benchmarks (e. g., the Pharmaceutical Supply Chain Initiative PSCI, Company benchmarks) as well as on structured internal interviews with BioNTech’s top executives. Read in the Sustainability Report 2022 how the perspectives of various stakeholder groups were taken into account.

CSR Fields of Action

Read in the Sustainability Report 2022 how we address the expectations of patients, investors, employees and business partners, climate protectors and NGOs campaigning for fair and equitable global access to novel medicines.

The Management Board and Supervisory Board work together for the benefit of BioNTech. They pursue the objective of sustainable value creation and have the interests of our shareholders, employees and other stakeholders equally in mind. These principles demand not only legal compliance but also ethically sound and responsible conduct. BioNTech is committed to respond to any event in which there are suspicions of a violation of our principles. Therefore, the BioNTech Ethics Contact Point offers an anonymous channel to report such events. 

Our Sustainability Reports also underline how responsible corporate governance ensures BioNTech's resilience.

By the end of 2022, BioNTech had more than 4,500 employees from over 80 nations. BioNTech’s number of employees has been growing continuously. As a biotechnology company, we are in intense competition for employees. After all, they form the basis of our corporate success.

Our human resources department, therefore, ensures that specialists are retained in the company, new talent is recruited and that we have global integration of our teams across all subsidiaries – new and old. In addition, the Sustainable Growth & Culture working group was established. Its aim is to actively shape a culture that promotes sustainable growth in the interests of all stakeholders. As an attractive employer, we also ensure the highest occupational safety standards for our employees.

Read in our Sustainability Report 2022 how we are shaping a sustainable corporate culture for growth.

The work we do has an impact on the environment. Production processes, the operation of R&D laboratories and planned major infrastructure and construction projects result in energy need, consumption of raw and auxiliary materials and the generation of waste.

We follow our successful path of growth in a Paris-aligned and environmentally conscious way and strive to be climate neutral by 2030.

Read in our Sustainability Report 2022 how we are creating value and growth within planetary boundaries.

We are convinced that BioNTech has a responsibility as a corporate citizen. We meet this responsibility with our corporate citizenship concept. The material topic "Caring for Patients" will be addressed and developed within this framework. In close cooperation with our business areas, we aim to use and promote the skills of our employees in a targeted and effective way through corporate volunteering activities. We attribute great importance to shaping our social commitment in a sustainable manner and in line with our corporate values.

The CSR program as a cross-divisional management tool

For all relevant issues identified in the materiality process, measures, objectives and implementation deadlines were described in the CSR program. By linking the materiality analysis to the CSR program, we ensure that all relevant stakeholder interests are taken into account.

Read our Sustainability Report 2022 to find out to what extent we met our CSR targets in 2022.

Read also

Stay up to date

Looking for our latest news, events or SEC filings?
Sign-up for our alerts here.